Understanding the importance of smart drugs in renal cell carcinoma.

[1]  D. Mukhopadhyay,et al.  Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma , 2005, Oncogene.

[2]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Lam,et al.  Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options , 2005, BJU international.

[4]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Brauch,et al.  Concomitant deregulation of HIF1α and cell cycle proteins in VHL-mutated renal cell carcinomas , 2005, Virchows Archiv.

[6]  L. Gunaratnam,et al.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.

[7]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[8]  R. Motzer,et al.  Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .

[9]  R. Motzer,et al.  AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .

[10]  D. Khayat,et al.  Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC) , 2005 .

[11]  J. Hainsworth,et al.  Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial , 2005 .

[12]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. North,et al.  Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. , 2005, Cancer letters.

[14]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[15]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[16]  D. Hicklin,et al.  Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies , 2004, Cancer Research.

[17]  Tim Eisen,et al.  Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[18]  J. Dutcher.  Mammalian Target of Rapamycin Inhibition , 2004, Clinical Cancer Research.

[19]  K. Alitalo,et al.  Immunodetection and quantification of vascular endothelial growth factor receptor‐3 in human malignant tumor tissues , 2004, International journal of cancer.

[20]  J. Patard,et al.  Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Motzer,et al.  Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Ratain,et al.  Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Steinberg,et al.  A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma , 2004, Journal of immunotherapy.

[24]  E. Raymond,et al.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Hicklin,et al.  A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.

[26]  H. Prats,et al.  Control of the Vascular Endothelial Growth Factor Internal Ribosome Entry Site (IRES) Activity and Translation Initiation by Alternatively Spliced Coding Sequences* , 2004, Journal of Biological Chemistry.

[27]  K. Bensalah,et al.  The changing evolution of renal tumours: a single center experience over a two-decade period. , 2004, European urology.

[28]  D. Mukhopadhyay,et al.  Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. , 2004, Seminars in cancer biology.

[29]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[31]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[32]  I. Mellinghoff,et al.  AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* , 2004, Journal of Biological Chemistry.

[33]  W Marston Linehan,et al.  The genetic basis of cancer of the kidney. , 2003, The Journal of urology.

[34]  L. Gunaratnam,et al.  Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[35]  R. Figlin,et al.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Harris,et al.  Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. , 2003, Cancer research.

[37]  K. Grankvist,et al.  Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma , 2003, Urological Research.

[38]  R. Motzer,et al.  Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma , 2003, Investigational New Drugs.

[39]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[40]  M. Iruela-Arispe,et al.  ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.

[41]  G. Neufeld,et al.  VEGF162, A New Heparin-binding Vascular Endothelial Growth Factor Splice Form That Is Expressed in Transformed Human Cells* , 2003, The Journal of Biological Chemistry.

[42]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[43]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[44]  Hui Chen,et al.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. , 2003, Journal of medicinal chemistry.

[45]  R. Motzer,et al.  Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma , 2003, Investigational New Drugs.

[46]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[47]  S. Wilhelm,et al.  BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.

[48]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[49]  J. Binder,et al.  Serum angiogenic activity: diagnostic relevance in renal cell carcinoma. , 2002, European urology.

[50]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[51]  D. Gillatt,et al.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.

[52]  S. Stacker,et al.  The role of tumor lymphangiogenesis in metastatic spread , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[54]  H. Lehr,et al.  Loss of tumor suppressor protein PTEN during renal carcinogenesis , 2002, International journal of cancer.

[55]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[56]  R. Johnson,et al.  Two HIFs may be better than one. , 2002, Cancer cell.

[57]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[58]  H. Radzun,et al.  Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas , 2001, Virchows Archiv.

[59]  C. A. Friedrich.  Genotype-phenotype correlation in von Hippel-Lindau syndrome. , 2001, Human molecular genetics.

[60]  Chi V. Dang,et al.  Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression* , 2001, The Journal of Biological Chemistry.

[61]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[62]  D. Mukhopadhyay,et al.  Role of Protein Kinase Cζ in Ras-mediated Transcriptional Activation of Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression* , 2001, The Journal of Biological Chemistry.

[63]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[64]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[65]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[66]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[67]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[68]  B. Seizinger,et al.  Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.

[69]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  W. Kaelin,et al.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  K. Alitalo,et al.  Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. , 1998, The American journal of pathology.

[73]  P. Einat,et al.  Translation of Vascular Endothelial Growth Factor mRNA by Internal Ribosome Entry: Implications for Translation under Hypoxia , 1998, Molecular and Cellular Biology.

[74]  A. Levy,et al.  Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR* , 1998, The Journal of Biological Chemistry.

[75]  M. Detmar,et al.  Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. , 1998, Molecular biology of the cell.

[76]  D. Mukhopadhyay,et al.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.

[77]  K. Alitalo,et al.  VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.

[78]  Y. Hirata,et al.  Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. , 1997, Genomics.

[79]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[80]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[81]  William Arbuthnot Sir Lane,et al.  Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II , 1995, Science.

[82]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[83]  Knudson Ag.  VHL gene mutation and clear-cell renal carcinomas. , 1995 .

[84]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[85]  T. Uchida,et al.  Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. , 1994, Cancer research.

[86]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[87]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[88]  J. Rossant,et al.  flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. , 1993, Development.

[89]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[90]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[91]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[92]  J. Rhim,et al.  Activated H-ras oncogenes in human kidney tumors. , 1988, Cancer research.

[93]  J. Haines,et al.  Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.

[94]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Mark Levine,et al.  Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  K. Grankvist,et al.  Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. , 2000, The Journal of urology.

[97]  Y. Fukushima,et al.  Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. , 1999, European journal of cancer.